X

Clinical Trials

Contact Us

Lung Cancer

EAY191-A3

Palbociclib and Binimetinib in RAS-Mutant Cancers: A ComboMATCH Treatment Trial


NRG-LU008

Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer


EAY191-E4 **Accrual to EAY191-E4 is Temporarily Suspended effective January 12, 2024**

ComboMATCH Treatment Trial E4: Nilotinib and Paclitaxel in Patients with Prior Taxane-Treated Solid Tumors


URCC 22063

Longitudinal Observational Trial to Uncover Subtypes of Cancer Cachexia (LOTUS-CC)


AFT-63

DNA Evaluation of Fragments for Early Interception – Lung Cancer Training Study (DELFI-L101 Study)


EAY191 (ComboMATCH) **If biopsy needed, TBD at MBMC**

Molecular Analysis for Combination Therapy Choice


SWOG S1900G

A Randomized Phase II Study of INC280 (Capmatinib) Plus Osimertinib with or Without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)


A021901 (JIT – If a possible patient is identified, notify CRA asap as it will take time to open trial through NCORP)

Randomized Phase II Trial of Lutetium Lu 177 Dotatate Versus Everolimus in Somatostatin Receptor Positive Bronchial Neuroendocrine Tumors


S2302 (Pragmatica)

A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) Plus Pembrolizumab (MK-3475; NSC 776864) Versus Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer


SWOG S1900E **Effective December 13, 2023 at 12:00 p.m. Pacific Time, Cohort 1 (co-mutation with TP53) of sub-study S1900E will be permanently closed to accrual as this cohort has met its protocol-specified accrual goal**

A Phase II Study of Sotorasib (AMG 510) in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (SWOG LUNG-MAP SUB-STUDY)